NCT00138177View on ClinicalTrials.gov

Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2011

Conditions
Recurrent Colon CancerRecurrent Rectal CancerStage III Colon CancerStage III Rectal CancerStage IV Colon CancerStage IV Rectal CancerUnspecified Adult Solid Tumor, Protocol Specific
Interventions
DRUG

oxaliplatin

Given IV

DRUG

leucovorin calcium

Given IV

DRUG

vorinostat

Given orally

DRUG

fluorouracil

Given IV

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00138177 - Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors | Biotech Hunter | Biotech Hunter